Lipoprotein ontology as a functional knowledge base by Chen, Meifania & Hadzic,  Maja
©2009 IEEE. Personal use of this material is permitted. However, 
permission to reprint/republish this material for advertising or 
promotional purposes or for creating new collective works for resale or 
redistribution to servers or lists, or to reuse any copyrighted component 
of this work in other works must be obtained from the IEEE. 
 
Lipoprotein ontology as a functional knowledge base 
Meifania Chen, Maja Hadzic 
Research Lab for Digital Health Ecosystems, Curtin University of Technology, Perth, Australia 
m.chen@curtin.edu.au, m.hadzic@curtin.edu.au 
 
Abstract- The advances of high throughput research in the 
biomedical domain have resulted in an onslaught of data being 
generated at an exponential rate. As a result, researchers face 
challenges in navigating through overwhelming amounts of 
information in order to derive relevant scientific insights. 
Ontologies address these issues by providing explicit description 
of biomedical entities and a platform for the integration of data, 
thereby enabling a more efficient retrieval of information. There 
have been major efforts in the development of biomedical 
ontologies in the recent years; however no such ontology exists 
for lipoproteins, which play a crucial role in various biological 
and cellular functions. Dysregulation in lipoprotein metabolism 
is significantly associated with an increased risk to 
cardiovascular disease, the leading cause of mortality in the 
world today. The aim of this paper is to propose a preliminary 
framework for Lipoprotein Ontology, with particular focus on 
the etiology and treatment of lipoprotein dysregulation. This 
may provide a novel and effective strategy for managing at risk 
individuals. 
I. INTRODUCTION 
Lipoproteins are a water-soluble “lipid+protein” complex 
which serves as a mode of transport for fats and cholesterol 
from the intestines to the liver, as well as endogenously 
synthesised lipids from the liver to tissues. They consist of a 
hydrophobic core of triglycerides and cholesteryl esters and 
are surrounded by a hydrophilic outer layer of phospholipids, 
cholesterol and apolipoproteins. Lipoproteins play a very 
crucial role in the regulation of biological and cellular 
functions in humans, and can be impacted by a number of 
factors, including obesity, diet/nutrition, physical exercise 
and other factors such as smoking and alcohol consumption. 
The complexities associated with lipoprotein dysregulation 
are continuously being revealed and addressed. However, as 
new information are constantly added to the massive pool of 
literature at a staggering rate, extracting relevant information 
proves to be a much harder challenge. Furthermore, 
lipoprotein research is an extensive area with a myriad of 
different research groups focusing on various aspects.  
Ontologies serve as a semantic framework which can be 
used for systematic annotation of information which can be 
derived from heterogeneous sources. This annotation allows 
for better understanding of the content of the information 
source as well as the intelligent retrieval of relevant 
information. Ontologies can also be employed as robust 
knowledge bases which will facilitate collaboration between 
different research groups. 
During the recent years there have been major efforts in the 
in the organising of biological concepts in the form of 
controlled terminologies or ontologies [15, 16, 17, 18]. The 
Unified Medical Language System (UMLS) is a repository of 
biomedical vocabularies which facilitates information sharing 
among various terminology systems [19]. The UMLS 
consists of three knowledge sources: Metathesaurus, 
Semantic Network, SPECIALIST Lexicon, as well as a 
number of supporting software tools. There are over 1 million 
biomedical concepts in Metathesaurus classified by 135 
semantic types and 54 relationships. Additionally, various 
biomedical ontologies in various disciplines are available via 
The Open Biomedical Ontologies in a standard format that 
allows systematic updating on the basis of community 
feedback [20]. The Gene Ontology (GO) project provides a 
set of dynamic, controlled vocabularies of gene products that 
can be applied in different databases to annotate major 
repositories for plant, animal and microbial genomes [17]. 
Protein Ontology annotates terms and relationships within the 
protein domain and classifies that knowledge to allow 
reasoning [21]. Most recently, Lipid Ontology was developed 
to provide a structured framework for the effective derivation 
of lipid-related information [22]. Lipid Ontology mainly 
serves as a formal annotation for the classification and 
organisation of information on lipids, with minor inclusion of 
the implications of disease on lipids. 
To date, there does not exist a formal ontology for 
lipoproteins. By creating annotations linking primary data to 
expressions in controlled, structured vocabularies, 
Lipoprotein Ontology will have a positive impact for ongoing 
lipoprotein research by making the data available to effective 
searching and algorithmic processing. Lipoprotein Ontology 
provides a formal framework for lipoprotein concepts and 
relationships that can be used to annotate database entries and 
support an intelligent retrieval of information. In addition, 
Lipoprotein Ontology enables efficient sharing of 
information, thereby promoting collaboration among various 
lipoprotein research groups. A key difference between 
Lipoprotein Ontology and other related ontologies is that 
Lipoprotein Ontology is developed with practical 
implications in mind. Lipoprotein dysregulation is becoming 
an increasingly serious concern with dire implications on 
health. By integrating all aspects of lipoprotein research, we 
can harness that knowledge into problem solving tools. As a 
result, Lipoprotein Ontology will not only provide a more 
efficient way of retrieving relevant information for the 
intended users, it will also support the querying of 
heterogeneous information sources from different aspects of 
lipoprotein research to achieve a common aim.  
II. SIGNIFICANCE OF LIPOPROTEIN ONTOLOGY WITHIN THE         
BIOMEDICAL DOMAIN 
Experienced scientists, clinicians and professionals are 
overwhelmed with huge, rapidly accumulating amounts of 
information on lipoproteins. There needs to be a systematic 
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approach to making use of an enormous amount of available 
information that has no value unless analysed and linked with 
other available information from the same domain. The three 
main problems are [23]: 
(1) The amount of the existing information. The size of the 
existing corpus of knowledge on lipoproteins is very large. 
The possibility of searching this information effectively is 
very low and in most cases some important information are 
neglected. 
(2) The dispersed nature of the information. Information 
regarding lipoproteins is dispersed over various resources and 
it is difficult to link this information, to share it and find 
specific information when needed. Additionally, the 
information contains a huge range of results. 
(3) The autonomous nature of the information sources. 
Most of the information resources develop their content 
independently. As a result of this, information available 
through different resources is heterogeneous in its format and 
content. This makes collective analyses of data very difficult. 
Additionally, many overlaps and redundancies are found in 
the data originating from different sources.  
Ontologies are increasingly being used within the 
biomedical domain to bring some order into this chaotic 
situation of exponential information growth. A large number 
of biomedical ontologies has already been developed, and 
these ontologies have been used in various ways. We have 
identified five key application areas for ontologies: 
1. Ontology-based collaboration between research teams 
2. Ontology-mediated information access, management 
and retrieval  
3. Ontology-based multi-agent systems 
4. Ontology-aided data mining 
5. Ontology-based web services 
Ontologies are useful in situations where collaboration 
between different research teams needs to be established in 
order to share complementary information and build a joint 
solution to their shared problem. Using an ontology to 
formalise the common knowledge will also reduce the 
possibility of duplicating experiments by different research 
groups (such as examining the same region of a DNA 
sequence), thus saving time and resources. This will create a 
cooperative environment, allowing coherence between 
different research teams in big research tasks. Gap analysis in 
lipoprotein research will also be easier. Research projects 
would be mapped onto the lipoprotein domain knowledge as 
specified by the ontology. During the planning stage, 
researchers could use these maps to see where overlaps, 
redundancies, complementary research and (more 
importantly) no research has occurred or is occurring. 
Lipoprotein Ontology can be designed to provide a 
conceptual model of lipoprotein concepts and relationships. 
This model can be used to form a semantic framework for 
information access, management and retrieval tasks. 
Lipoprotein Ontology can be used for systematic annotation 
of lipoprotein information available through various 
information resources. The annotation of information enables 
searching for the meaning of information over its appearance 
in the text, and in this way, allows for intelligent querying of 
heterogeneous information sources and retrieve relevant 
information. Most of the current search engines do not 
operate in this way as they search for a particular string of the 
letters and not for the meaning of the word. Consequently, 
such search engines often retrieve voluminous results that are 
completely outside the domain the user is interested in. 
Furthermore, ontologies can also be used as mediators to 
bridge the heterogeneities between different data resources, 
information services and user applications.  
Powerful systems can be designed when ontologies are 
integrated with multi-agent technologies [24]. Ontologies can 
be used as coherent and consistent knowledge bases of 
different agents. A collection of agents can utilise shared 
domain ontology as their common knowledge base. This will 
facilitate communication and coordination between agents 
and support some important processes within a multi-agent 
system such as: problem decomposition and task sharing 
among different agents, results sharing and analysis, 
information retrieval, selection and integration. Ontology and 
multi-agent technologies can be used together to enable 
efficient and effective access, extraction and manipulation of 
the information from various information resources. 
Data mining is a set of processes that is based on 
automated searching for actionable knowledge buried within 
a huge body of data.  Data mining extracts information and 
finds patterns and behaviours embedded in the data. 
Lipoprotein Ontology is machine-understandable and allows 
automatic data analysis programs such as data mining to 
access, understand and analyse the ontology-structured 
information. When applied on lipoprotein data, data mining 
algorithms can play a crucial role in deriving new knowledge 
within the lipoprotein domain. The results have the potential 
to increase the understanding of the dynamics involved in the 
lipoprotein pathways and help making predictive models for 
decision making and new discoveries. This new knowledge 
can be used to assist in the (1) prevention, diagnosis, 
treatment and control of dyslipidemia, (2) improvement of the 
infrastructure for evidence-based interventions and (3) 
introduction of innovations for improvement in health care. 
The importance of ontologies within the Web Services 
community is significant as ontologies can provide a semantic 
framework that will enable knowledge sharing and use by all 
parties involved. In some of our works [25, 26] we have 
explained how Ontology technology in combination with 
Grid technology can help create collaborative environments 
and increase interoperability within the system.  
III. LIPOPROTEIN ONTOLOGY MODEL 
As lipoprotein research is an extensive area with a 
multitude of different research groups working disparately to 
achieve different aims, the need for a common information 
repository is warranted in order to fully appreciate the 
implications of lipoprotein dysregulation. By incorporating 
specific aspects of lipoprotein research in Lipoprotein 
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Ontology, not only in terms of the classification of 
lipoproteins, but also understanding the metabolic pathways, 
pathophysiology, causes and treatment of abnormal 
lipoprotein levels, this impacts not only on identifying the 
risks, but also provides effective preventative measures.  
In this paper, we propose a preliminary model for 
Lipoprotein Ontology using Protégé, which consists of five 
sub-ontologies: 
1. Classification – different classes of lipoproteins 
2. Metabolism – lipoprotein metabolism pathways 
3. Pathophysiology – understanding the interactions 
between various lipoproteins crucial to understanding 
lipoprotein dysregulation  
4. Etiology – establishing the causes that might cause 
lipoprotein dysregulation 
5. Treatment – management of lipid dysregulation 
An overview of Lipoprotein Ontology is shown in Fig. 1. Each of 















Fig. 1. Lipoprotein Ontology model consisting of five sub-
ontologies. Sub-ontologies comprise of classification, metabolism, 
pathophysiology, etiology and treatment. Their respective sub-
classes, depicted as triangles will be expanded in detail below. 
 
A. Classification 
Lipoproteins are classified according to size and density, 
i.e. chylomicrons, very-low density lipoproteins (VLDL), 
intermediate density lipoproteins (IDL), low density 
lipoproteins (LDL), high density lipoproteins (HDL), ranging 
from largest and least dense to smallest and most dense [27].  
Apolipoproteins are lipid-binding proteins which serve as 
enzyme modulators and receptor ligands that regulate the 
intravascular metabolism of lipoproteins and their tissue 
uptake. 
B. Metabolism 
Lipoprotein metabolism is divided into two pathways, 
exogenous, the transport of dietary lipids from the intestines 
to the liver and peripheral tissues, and endogeneous, the 
transport of lipids produced in the liver to peripheral tissues. 
As lipoprotein metabolism is highly complex, involving a 
number of different pathways, this will be further elucidated 
in our future work. 
C. Pathophysiology 
Dyslipidemia is defined by abnormal levels of lipoproteins. 
Some characteristics of lipoprotein dysregulation include high 
concentrations of low-density lipoproteins (LDL) cholesterol, 
low high-density lipoproteins (HDL) cholesterol and high 
plasma triglycerides [3].  
D. Etiology 












Fig. 2. Ontology model of etiology of lipoprotein dysregulation. 
Sub-ontologies include genetics, lifestyles, which are further sub-
divided into exercise, diet, smoking alcohol and emotional 
wellbeing, as well as drug interactions, which are further sub-
divided into corticosteroids and beta-blockers. 
 
Lifestyle contributes to most cases of dyslipidemia in 
adults. The most prominent cause in industrialised countries 
is a sedentary lifestyle with lack of physical exercise and 
excessive dietary intake of saturated fat and cholesterol. 
Other common causes include smoking, alcohol consumption 
and stress [28, 29].  
Drug interactions may also contribute to lipoprotein 
dysregulation. Some examples are corticosteroids [30,31]  
and beta-blockers [32].  
Genetic mutations may result in either the overproduction 
or defective clearance of LDL cholesterol and triglycerides, 
or the underproduction or excessive clearance of HDL [33].  
E. Treatment 












Fig. 3. Ontology model of treatments for lipoprotein 
dysregulation. Sub-ontologies include combination therapy, drugs, 
further sub-divided into statins, fibrates, bile acid sequestrants and 
cholesterol absorption inhibitors, as well as lifestyle changes, further 
sub-divided into weight loss, dietary supplements and physical 
exercise. 
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First line approach includes lifestyle changes such as 
weight loss, exercise and dietary modification [2]. Dietary 
supplements include the following:  
Fish oil has been reported to reduce plasma triglyceride 
concentrations by up to 40% [34]. Increasing evidence 
suggest that fish oil consumption protects against coronary 
disease [35, 36].  
Nicotinic acid (niacin) in vitamin B3 blocks the 
metabolism of fats in adipose tissue, leading to a decrease in 
free fatty acids in the blood and decreased hepatic secretion 
of VLDL and cholesterol [37]. Niacin also increases HDL by 
promoting HDL production and inhibiting HDL clearance.  
Antioxidants inhibit the oxidation of toxic LDL and is 
inversely correlated with cardiovascular risk. Examples of 
antioxidants are vitamin A, vitamin E and vitamin C. 
Dietary supplements that lower LDL cholesterol levels 
include fiber supplements and products containing plant 
sterols (phytosterols). Plant sterols reduce LDL cholesterol by 
10%-15% by inhibiting cholesterol incorporation into 
micelles, decreasing the absorption of total cholesterol [38].  
In addition to lifestyle changes, several lipid-regulating 
agents may be used to improve dyslipidemia [39, 40]. 
Statins are possibly the treatment of choice for reducing 
LDL cholesterol as they demonstrably reduce cardiovascular 
mortality. Statins inhibit hydroxymethylglutaryl CoA 
reductase, a key enzyme in cholesterol synthesis, leading to 
up-regulation of LDL receptors and increased LDL clearance 
[41, 42]. They reduce LDL cholesterol by up to 60%, produce 
small increases in HDL and modest decreases in triglycerides 
through the reduction of VLDL [12, 43]. Recent clinical trials 
have demonstrated that statins can decrease cardiovascular 
events, irrespective of the initial level of cholesterol [43, 44]. 
Fibrates reduce triglycerides by about 50% and 
significantly lowers VLDL content. Clinical studies have 
shown that fibrates can reduce cardiovascular events in high-
risk subjects [45, 46]. The mechanisms of action of fibrates 
on lipoprotein metabolism have been elucidated in various 
experimental studies [47].  
Bile acid sequestrants have been proven to reduce 
cardiovascular mortality. They prevent the reabsorption of 
intestinal bile acid, forcing the up-regulation of hepatic LDL 
receptors to recruit circulating cholesterol for bile synthesis, 
leading to a decrease in LDL levels [48].  
Cholesterol absorption inhibitors inhibit intestinal uptake 
of both dietary and hepatic cholesterol. They lower LDL 
cholesterol by 15 to 20% and causes small increases in HDL 
and a mild decrease in triglycerides [49]. Cholesterol 
absorption inhibitors have been reported to have a potent 
effect when combined with statin therapy, and is extremely 
beneficial for statin-resistant or statin-intolerant populations.  
Combination therapy involves the use of dual or multiple 
lipid-regulating agents to treat lipoprotein abnormalities by 
targeting specific lipoproteins and utilising the 
complementary mechanisms of action of the different agents 
[50]. This is a more effective treatment strategy where lipid-
regulating monotherapy (e.g. statins or fibrates) may not 
provide adequate improvement in dyslipidemia. However, 
there are some contraindications between different 
treatments. Although beneficial in correcting dyslipidemia, 
the combinations of statins with fibrates or niacins have the 
potential for interactions that increase the risks of adverse 
effects, such as myositis and hepatotoxicity [51]. Hence, 
treatment of lipoprotein dysregulation warrants a thorough 
examination of lipoprotein profiles of specific individuals. 
 
IV. CONCLUSION 
Dyslipidemia is a central feature of the metabolic syndrome 
characterised by increased levels of LDL cholesterol, reduced 
HDL-cholesterol and elevated plasma triglycerides. The 
prevalence of the metabolic syndrome is increasing at an 
exponential rate in developed countries as a result of 
sedentary lifestyles. This is a crippling problem as lipoprotein 
dysregulation is significantly associated with increased risk to 
cardiovascular disease, the leading cause of mortality in the 
world today.  
As researchers continue to grapple with the depth and 
breadth of information within the literature, Lipoprotein 
Ontology attempts to delineate the problem into five key 
areas which cover the classification of lipoproteins, pathways 
of lipoprotein metabolism, pathophysiology of lipoproteins, 
causes of lipoprotein dysregulation as well as treatment of 
dyslipidemia. Not only will this provide a more efficient way 
of retrieving relevant information for the intended users, this 
technology will also support the querying of heterogeneous 
information sources from the different aspects of lipoprotein 
research to achieve a common aim. The end result would be a 
complete repository of lipoprotein knowledge and research in 
one program for the perusal of physicians, researchers and 
patients.  
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